Podcasts about Receptor

01. Skrimor - Banana Shoes 02. Mntl, Grinder - Western 03. Metanoia - In The Club 04. Midnight Cvlt - Back Home 05. Donny & Kathrsys - The One (Audio Remix) 06. Nbc9 - Bankers Ghost (Diode Remix) 07. Receptor, Yush! - Ambabai (Task Horizon Remix) 08. Punchman - Stuzha 09. Mob Tactics - 9mm 10. Audio - Red Flag 11. Zombie Cats & Nemean - Hulk 12. Kryptomedic, Akrom - Fake Reality 13. Trcd - Faceplant 14. Neonlight - Purple Radiance 15. Cyfunk - Shout for Rebel 16. Sindicate - Snake Oil 17. Symplex - Undead 18. Fractalone - Stand Up 19. Cliques - Scorpions (Hologram Remix) 20. Forbidden Society - Cobra (TR Tactics Remix) 21. Fascad - Dark Triad 22. Hackwaves - Back Door 23. Paperclip & 1nverter - Ultrafunk 24. Task Horizon - Forbidden Planet (Ed Rush Remix) 25. Redpill - The Siren (Audio Remix) 26. Chaser - Lose Control 27. Nemean - The Torrent (Redpill Remix) 28. Prolix, Al, So - Bassline Shotta (Skrimor Remix) 29. Project Zeus - Burn It Up 30. Bad Company - Planet Dust (Latte Remix) 31. Gangladesh - Angel Slayer 32. Ill-fated - Venom 33. Blinded Theory - Crows 34. Misanthrop - Flashback 35. Merikan - Snarling Wolf 36. Burr Oak - Uno (Vici Remix) 37. Gino - Du Du Du 38. Misanthrop - Bla Bla 39. Bodrak - Basement 40. Nemy - Ebonwild 41. Bennie - Dark Carnival 42. Dunk - Dark Machine 43. Instinkt - Rogue 44. Calyx - Before Dawn 45. Glitch City, Leaf - Spirit World 46. Noisia, The Upbeats - Dead Limit (Simula Remix) 47. Audio - Orlok 48. Nerv3 - Osc 49. A-cray - No Return 50. Entity - Scimitar 51. Mndscp - Raw 52. Tryst Temps - Seth 53. Mntl - Magical Move 54. Slwdwn - Dread 55. Bad District - Loki 56. Prdk, Zigi Sc - NET 57. Tesseracts - DERBY 58. Absu_ntql - Dread 59. Tmvt - Nightfall 60. 2whales - oy to ne vecher 61. Aim - Autoimmune 62. Ebony Dubsters - Ra (Diode Remix) 63. Fourward - Put In Work 64. Nickbee - Lights Out 65. Prfct Mandem - Jungle is Massive (Jade Venom Remix) 66. Task Horizon, Killa P - Like This (Skrimor Remix) 67. The Radiance - Signature 68. Sindicate - Bad Bwoii 69. Place 2b - Badduss 70. Screamarts - Metamorphosis 71. Parallel - Party Time 72. Fuze - Initium 73. Parallel - Filter Freak 74. Nimeim - Time 75. Simons, Laminar, Vindon - Samurai 76. Killin' Void - SABOTAGE feat. sanna frankie 77. Tesseracts - Intelligent Killer 78. Tom Finster, Cuepric, Novalu - Left Room 79. Rockwell - Only 80. Forbidden Society - Addict (Vici Remix) 81. Gourski, Manta - Element 82. Hissteria - HEAVYWEIGHT SOUND 83. Chom, Coppa - Badboy Material 84. Detch, Rerun - Get Down 85. Tom Finster, Vorso - Keep On 86. E. Krilatov - Kacheli (Softskilla bootleg) 87. Rueben, Freddy B - Get It Right 88. Iam Yimm - Cause A Vibe 89. Envy - Love Talk

You might think you can't quit sugar because you lack discipline, but the truth is your brain runs sugar on the same reward circuit as cocaine, and no amount of willpower beats a system that's been physically rewired against you. I'll show you exactly what's happening in your brain and gut, and give you three things you can do starting tonight to break the cycle for good. Fix the root, and the cravings follow.  CLICK HERE TO BECOME GARYS VIP!: https://bit.ly/4ai0Xwg Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKpCYMBIOTIKA: "BRECKACYM30" FOR 30% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - Intro of show 01:21 - The 10 PM fridge problem 01:46 - Sugar and the cocaine comparison 02:16 - Your brain's reward circuit 02:39 - The dopamine and opioid two for one hit 03:00 - Receptor downregulation and tolerance 03:13 - What the 2025 review found 03:39 - Why willpower can't win 04:00 - The gut microbiome craving loop 04:30 - Dysbiosis and the Western diet 04:49 - Biology problem, not character flaw 05:30 - Tool one: the 10 minute water rule 06:40 - Tool two: 30 grams of protein in the morning 07:13 - Tool three: crowd sugar out with fiber and fat 07:55 - The full 30 day protocol 08:19 - Days three to five: where people quit 09:03 - What to do starting tonight Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions.  Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode Dr. Gillian Beauchamp sits down with Dr. Stephanie Weiss to discuss research examining GLP-1 receptor agonists in the treatment of Alcohol Use Disorder.

Dr. Monty Pal and Dr. Rachna Shroff explore how GLP-1 receptor agonists impact progression and survival in GI cancers, examining current retrospective data, immune microenvironment biology, and the need for prospective trials. LINK TO FULL TRANSCRIPT

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest scientific advancements, regulatory milestones, and strategic business maneuvers shaping the industry. One of the standout developments comes from Otsuka with their drug Voyxact, which has shown promising results in stabilizing kidney function decline in patients with immunoglobulin A nephropathy (IgAN). In a Phase 3 trial, patients exhibited kidney function comparable to that of healthy adults. IgAN is a challenging autoimmune condition often leading to end-stage renal disease. This advancement, leveraging a monoclonal antibody to target specific pathways, could mark a new era in managing this chronic kidney disease. In oncology, Jiangsu Alphamab Biopharmaceuticals has been making waves through strategic collaborations, securing deals worth $125 million upfront and potential milestone payments reaching over $2 billion. Their focus on developing antibody-drug conjugates (ADCs) using AI and machine learning underscores the promise of precision oncology. ADCs marry the targeting precision of antibodies with potent anti-cancer drugs, highlighting robust investment and confidence in these cutting-edge therapies. Merck & Co. continues to expand its financial outlook, driven by the success of its flagship drugs like Keytruda. This monoclonal antibody remains pivotal in cancer immunotherapy, while drugs like Winrevair and Lipfendra are broadening Merck's reach into cardiovascular health. This growth trajectory reflects a strategic push toward diversifying product lines and leveraging breakthrough therapies to maintain strong financial performance. Additionally, Merck's $10.8 billion acquisition of Prometheus Biosciences aims to expand their therapeutic portfolio with targeted biologics. Although mid-stage trials showed mixed results for their anti-TL1A antibody therapy, such acquisitions are pivotal in addressing unmet medical needs. On the regulatory side, Sanofi's MenQuadfi vaccine has achieved EU approval for use in infants as young as six weeks. This approval enhances preventive measures against invasive meningococcal disease in vulnerable populations, representing a significant public health advancement. In research methodologies, Sethera Therapeutics' collaboration with Receptor.AI is notable. By integrating AI-driven platforms for polymacrocyclic peptide discovery aimed at hard-to-drug targets, they're paving the way for overcoming traditional drug discovery challenges through computational tools. However, not all news is about progress. Jazz Pharmaceuticals faced a setback by withdrawing its label indication for Zepzelca after failing Phase 3 trials for small-cell lung cancer. This underscores the inherent risks in clinical development pathways. From a financial standpoint, BioNTech has adjusted its 2025 sales forecast downward due to waning global demand for COVID-19 vaccines—a reflection of the volatile vaccine markets post-pandemic peaks. Meanwhile, Pfizer's discontinuation of its Phase 2 GIPR antagonist for obesity illustrates strategic pivots within R&D pipelines as companies reassess priorities based on trial outcomes and market potential. Recent corporate strategies include Pfizer's ambitious cost-saving plan totaling $9.7 billion through 2029. Amid economic pressures and patent expirations looming on key products like Eliquis, Pfizer is optimizing operations to stay competitive. Speculation around a possible merger between Bristol Myers Squibb (BMS) and AstraZeneca has stirred interest. With both facing patent cliffs, this merger could rejuvenate portfolios—though the strategic benefits for AstraZeneca are still debated. On the technological front, advancements in cellular therapies promise to revolutionize medicine production at the cellular level, potentially enhancing patient outcomes through more personalized treatments. The regulatory landscape is also evolving. There's a growing call for streamlining Investigational New Drug applications under the FDA's Trialblazer initiative—crucial for accelerating clinical trials and bringing innovative therapies to market swiftly. Finally, initiatives such as Boston Scientific's restructuring efforts highlight challenges within the medical device sector as companies adapt to shifting market dynamics. Overall, these developments underscore an industry in motion where innovation and adaptation are key to navigating complex landscapes and advancing patient care globally. As we look ahead, these trends will likely continue shaping the future of pharmaceuticals and biotech in profound ways.Support the show

Dr. Ajay Nayak interviews Dr. Christopher Pascoe about his article, "19(S)-Hydroxyeicosatetraenoic Acid Promotes Airway Smooth Muscle Relaxation and Decreases DNA Synthesis Through the Prostacyclin Receptor."

Propofol, a cornerstone in anesthesia practice, functions as a positive allosteric modulator at the GABA-A receptor. This episode explores its receptor pharmacology, the mechanisms behind its dose-dependent clinical effects, and addresses common questions like propofol infusion syndrome and pain on injection.Receptor pharmacology and allosteric modulationPharmacokinetics and context-sensitive half-timeCardiac and respiratory effectsRisk and management of propofol infusion syndromeHandling egg allergy concernsStrategies to reduce pain on injectionFREE RESOURCE FOR THIS EPISODE:GPCR Cheat Sheet — G-protein coupled receptors decoded for anesthesia. Head to atomicanesthesia.com/freebies/gpcr-cheat-sheet to grab it free.MORE FREE STUDY RESOURCES:SEE/NCE Study Plan — A structured, week-by-week plan to pass your boardsNon-Opioid Pharmacology Cheat Sheet — Every non-opioid analgesic you need to know, on one pageMalignant Hyperthermia Reference Guide — Recognize MH fast. Treat it faster — one-page referenceWANT THE FULL PLATFORM?Atomic Anesthesia is the all-in-one study platform built specifically for SRNAs — lessons, quizzes, flashcards, and more. Start your free trial at atomicanesthesia.com.Mentioned in this episode:

Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: Multi-target trial emulation study BMJ Open This retrospective cohort study using target trial emulation evaluated the association between use of newer glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide, tirzepatide) and alcohol-related hospitalizations among adults with alcohol use disorder (AUD) and type 2 diabetes (T2D) or obesity. The authors found that among adults with AUD and T2D or obesity, initiation of newer GLP-1 RAs was associated with a lower observed risk of alcohol-related hospitalization.    Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Discutimos al receptor Stefon Diggs como posible refuerzo de Kansas City Chiefs, qué esperamos del receptor CeeDee Lamb de Cowboys en 2026 y más.=============

Could GLP-1 receptor agonists be used to treat binge eating disorder? Binge eating disorder is one of the most common eating disorders, yet treatment options remain limited. Now widely used for type 2 diabetes and weight management, Glucagon-like peptide (GLP)-1 receptor agonists act on pathways involved in appetite and food intake, but little is known about how these medications affect disordered eating behaviours, including binge eating, emotional eating, loss of control eating, and dietary restraint. In this episode, Dr Ilaria Costantini joins eClinicalMedicine Senior Editor Victoria Higgs to discuss her new systematic review and meta-analysis, which draws on data from 25 clinical trials and more than 8000 participants, alongside valuable personal insights from people with lived experience. They explore evidence that GLP-1 receptor agonists may reduce binge eating-related behaviours, while also considering concerns that these medications could affect eating restraint or body image in a harmful way and why psychological support might be key for their use. This conversation examines the limitations of current evidence and next steps for research at the intersection of metabolic medicines and eating disorders. Click here to read the full article: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00256-7/fulltext

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from July 3-10, 2026.

In this episode, Nicholas P. McCormic discusses new real-world research from the RISE registry examining the use of GLP-1 receptor agonists in patients with rheumatic and musculoskeletal diseases. He explains the motivation behind the study, its design, and key findings on medication use, weight loss, and differences between semaglutide and tirzepatide, while highlighting important considerations for clinicians and patients. Nick also shares insights into the strengths and limitations of using registry data before reflecting on his journey from psychology and sociology to earning a Ph.D. focused on chronic disease management and rheumatology, offering advice for aspiring researchers and a look at his future work. 

Highlights from the PER® CME activity "Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, focusing on precision oncology in non-small cell lung cancer (NSCLC), experts Helena Yu, MD; Jacob Sands, MD; and Sarah Goldberg MD, MPH; will discuss the rapidly evolving landscape of Human Epidermal growth factor Receptor 2 (HER2)- and Trophoblast cell-surface antigen 2 (TROP2)-directed therapies in NSCLC. The podcast covers the spectrum of targeted agents from antibody-drug conjugates (ADCs) to novel HER2-selective tyrosine kinase inhibitors (TKIs), along with key clinical trial data and practical strategies for managing the unique adverse event profiles associated with these treatments.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/medical-crossfire-precision-oncology-in-nsclc-translating-her2-and-trop2-innovation-into-practice-changing-care-mr5qThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In this episode, we explore GLP-1 receptor agonists and their role in managing type 2 diabetes. We'll discuss how they work, their clinical benefits, routes of administration, common adverse effects, drug interactions, and key counseling points—all explained in a clear and practical way for healthcare professionals, students, and anyone interested in diabetes care.References: American Diabetes Association (ADA) Standards of Care in Diabetes, NCBI StatPearls, and official prescribing information.

Gabriel Nunez discusses the discovery of NOD-like receptors, NOD1 and NOD2, in inflammatory bowel disease and how travel and taking a moment to enjoy local culture and art influences his creativity. Host: Cindy Leifer Guest: Gabriel Nuñez Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server HLA and antigen presentation (Hum Immunol, 1987) Bcl2, cell death, and B cells (Nature, 1991) Discovery of NOD1 (J Biol Chem, 1999) Discovery of NOD2 (J Biol Chem, 2001) Mutation in NOD2 and connection to Crohn's disease (Nature, 2001) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.  

Discutimos al receptor Keenan Allen como opción para Colts, quién será el receptor #2 de Jets y más reportes NFL.=============

Haces todo "bien" (rutinas, libros, metas) pero tu vida sigue exactamente igual? El problema no es lo que haces, es la señal que estás proyectando sin darte cuenta. En este episodio analizamos a profundidad los principios de "Proyector de Realidad Separada" del físico Vadim Zeland. Descubre por qué la realidad siempre responde con retraso, cómo tu día a día secuestra tu punto de atención, y cuál es la diferencia exacta entre un "Receptor" (que reacciona al caos) y un "Transmisor" (que proyecta su propia película). Lo que vas a descubrir en este episodio: Por qué hacer las cosas "bien" (leer, madrugar, tener metas) ya no te está funcionando. El principio del Espejo: la razón por la que la realidad siempre responde con retraso (y por qué la mayoría se rinde aquí). La trampa del "Receptor": cómo tu día a día secuestra tu atención sin que te des cuenta. La "Reacción Atípica": el movimiento exacto que debes hacer cuando el día te golpea y todo sale mal. La herramienta de Zeland: cómo calibrar tu cerebro por la mañana y por la noche para dejar de emitir estrés. RETO PARA DESBLOQUEAR EL SIGUIENTE EPISODIO: Si llegamos a 500 Me Gusta y 300 Comentarios, libero de inmediato el análisis avanzado de "El Hacedor de Realidades". Para participar, deja en los comentarios la frase: "Hoy fui Receptor cuando..." y complétala con total honestidad sobre algo que te haya pasado esta semana. ⚙️ EL PROTOCOLO DE LOS 4 MOMENTOS (GRATIS): El conocimiento sin estructura diaria se evapora. Si quieres la guía exacta que yo utilizo para mantener mi proyector calibrado por la mañana y por la noche: Escribe la palabra TRANSMISOR en los comentarios y te haré llegar el acceso sin intermediarios. #vadimzeland #transurfing #mentalidad #conocimientoexperto #hábitos #ProyectorDeRealidad #salvadormingo Salvador Mingo Conocimiento Experto CONECTA CONMIGO: Contacto: salvador@conocimientoexperto.com Enlaces oficiales: Web: https://conocimientoexperto.com YouTube: https://www.youtube.com/@conocimientoexperto Podcast (Spotify): https://spoti.fi/2yS9p38 Instagram: https://www.instagram.com/salvadormingo/ LinkedIn: https://www.linkedin.com/in/salvadormingoce/

Haces todo "bien" (rutinas, libros, metas) pero tu vida sigue exactamente igual? El problema no es lo que haces, es la señal que estás proyectando sin darte cuenta. En este episodio analizamos a profundidad los principios de "Proyector de Realidad Separada" del físico Vadim Zeland. Descubre por qué la realidad siempre responde con retraso, cómo tu día a día secuestra tu punto de atención, y cuál es la diferencia exacta entre un "Receptor" (que reacciona al caos) y un "Transmisor" (que proyecta su propia película). Lo que vas a descubrir en este episodio: Por qué hacer las cosas "bien" (leer, madrugar, tener metas) ya no te está funcionando. El principio del Espejo: la razón por la que la realidad siempre responde con retraso (y por qué la mayoría se rinde aquí). La trampa del "Receptor": cómo tu día a día secuestra tu atención sin que te des cuenta. La "Reacción Atípica": el movimiento exacto que debes hacer cuando el día te golpea y todo sale mal. La herramienta de Zeland: cómo calibrar tu cerebro por la mañana y por la noche para dejar de emitir estrés. RETO PARA DESBLOQUEAR EL SIGUIENTE EPISODIO: Si llegamos a 500 Me Gusta y 300 Comentarios, libero de inmediato el análisis avanzado de "El Hacedor de Realidades". Para participar, deja en los comentarios la frase: "Hoy fui Receptor cuando..." y complétala con total honestidad sobre algo que te haya pasado esta semana. ⚙️ EL PROTOCOLO DE LOS 4 MOMENTOS (GRATIS): El conocimiento sin estructura diaria se evapora. Si quieres la guía exacta que yo utilizo para mantener mi proyector calibrado por la mañana y por la noche: Escribe la palabra TRANSMISOR en los comentarios y te haré llegar el acceso sin intermediarios. #vadimzeland #transurfing #mentalidad #conocimientoexperto #hábitos #ProyectorDeRealidad #salvadormingo Salvador Mingo Conocimiento Experto CONECTA CONMIGO: Contacto: salvador@conocimientoexperto.com Enlaces oficiales: Web: https://conocimientoexperto.com YouTube: https://www.youtube.com/@conocimientoexperto Podcast (Spotify): https://spoti.fi/2yS9p38 Instagram: https://www.instagram.com/salvadormingo/ LinkedIn: https://www.linkedin.com/in/salvadormingoce/Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/conocimiento-experto--2975003/support.

01. VETRÁ, Polovinka - Сохранить тебя 02. BULA, SVNV, Swanky Tunes - Тлеет (Remix) 03. МакSим x Bebe Rexha, Faithless - Отпускаю (Nei Blend) 04. Bagryana Nebo - На высоких каблуках 05. Нюша - Цунами (Different Guys Remix) 06. Динамит - Моя Ми (DJ Niki & DJ Rich-Art Remix) 07. RYZE - Кассета старых чувств 08. ХЛЕБ - Плачу на техно 09. iskrit - другая сторона 10. Люся Чеботина x BAUSA - Каблук (DJ BALDIN Edit) 11. Big Baby Tape x PAWSA - Chuchuka (Nei Blend) 12. NILETTO - Любимка 13. Ваня Дмитриенко, SALUKI - Ладони 14. Moreart - Tom Ford (Nei Blend) 15. Инфинити - Слезы вода 16. Крыли - Плинтус 17. NEMIGA - Довольна 18. SEREBRO - Дай мне шанс 19. Стас Экстаз - Я крокодил 20. MIA BOYKA - Гагарин 21. DJ SMASH - Moscow Never Sleeps 22. 4eholl, SHALUTA - Просто люби 23. Наташа Королёва x Swedish House Mafia - Маленькая страна (DJ BALDIN Edit) 24. NLO, Оксана Почепа (Акула) - Такая любовь 25. Mirèle, ЛСП - Вернись домой 26. Receptor - Привет

This podcast explores the growing concern of muscle loss associated with GLP-1 receptor agonist therapy for obesity management. It highlights the need for greater awareness among clinicians and patients, emphasizing strategies such as adequate protein intake, strength training, and emerging pharmacologic options to preserve muscle mass. The discussion underscores the importance of muscle preservation for long-term health and quality of life in individuals using GLP-1 therapies. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

A retrospective comparison of two state-funded smartphone-based contingency management programs with different incentives  Drug and Alcohol Dependence This retrospective study compared outcomes for patients with stimulant use disorder enrolled in a smartphone-based contingency management program based on the amount of total incentives possible, either $75 (“low-value”) or $599 (“moderate-value”). The low-value program was based in New Jersey, funded through SAMHSA (which limited reimbursement to $75/patient at the time of implementation, which has since been increased), and rewarded completing drug testing, attending counseling visits, and completing CBT modules rather than abstinence over 16 weeks. The moderate-value program was funded by West Virginia's Medicaid managed care organizations, lasted up to 26 weeks, and largely rewarded negative drug screening results, with additional rewards for counseling and CBT modules. Patients in the moderate-value program submitted significantly higher rates of negative substance tests (36%, with an average of 3.2 negative tests) compared to those in the low-value group (24.7%, with an average of 24.8 negative tests).   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification.“Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, examine the growing evidence for GLP-1 receptor agonists in rheumatological disease — drugs originally developed for glycemic control that are now drawing serious attention as potential immunomodulators with implications across the specialty.The conversation opens by tracing the arc of GLP-1 agonist development, from exenatide's approval in 2005 through to semaglutide's landmark cardiovascular and renal data in the SELECT1 and FLOW2 trials, before turning to the question now quietly circulating in rheumatology clinics: are these drugs doing something beyond shifting weight?

Adherence drives outcomes: Lead your team in proactive AE care for high-risk EBC success. Credit available for this activity expires: 5/26/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/interprofessional-approach-adverse-event-care-patient-high-2026a1000gez?ecd=bdc_podcast_libsyn_mscpedu

The GLP-1 receptor agonists reduce appetite and greatly facilitate weight loss. Robert Kushner, MD, of Northwestern University Feinberg School of Medicine joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss appropriate diet and exercise recommendations for patients receiving GLP-1 receptor agonists for weight loss. Related Content: Lifestyle Modification and Incretin-Based Therapy for Obesity The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era

Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass

Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass

Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass

This podcast is a brief review of emerging literature focusing on the potential use of GLP-1 receptor agonists in the treatment of mental health and substance use disorders. The episode explores how GLP-1 receptor agonists work to alter neurotransmitter systems and impact inflammation in the brain.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month, they discuss: Marston NA, Bohula EA, Bhatia AK, et al. "Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277 Lee YJ, Lee SJ, Kim JW, et al. "Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283 Nissen SE, Wolski K, D'Alessio D, et al. "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767 Moura FA, et al. "Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238 Ostrominski JW, Ortega-Montiel J, et al. "Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063 Nicole Napoli, "Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

Amanda Banks is a consultant and a physician at the Corporal Michael J. Crescenz VA Medical Center. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A. Banks. GLP-1 Receptor Agonists and Eating Disorders — Cause for Concern. N Engl J Med 2026;394:1665-1667.

Katherine Nautiyal discusses her paper, "The Serotonin 1B Receptor Modulates Striatal Activity Differentially Based on Behavioral Context," published in Vol. 13, Issue 2 of eNeuro, with Reviewing Editor Jibran Khokhar. Find our upcoming webinar schedule here. With special guest: Katherine Nautiyal   Hosted by: Jibran Khokhar On Neuro Current, we delve into the stories and conversations surrounding research published in the journals of the Society for Neuroscience. Through its publications, JNeurosci, eNeuro, and the History of Neuroscience in Autobiography, SfN promotes discussion, debate, and reflection on the nature of scientific discovery, to advance the understanding of the brain and the nervous system. Find out more about SfN and connect with us on BlueSky, X, Instagram, and LinkedIn. 

A µ-opioid receptor superagonist analgesic with minimal adverse effects Nature This study identifies a novel µ-opioid receptor (MOR) agonist with supramaximal intrinsic efficacy and a unique pharmacological profile that produced effective analgesia in rodents with minimal adverse effects. N-desethyl-fluornitrazene (DFNZ) was derived from a class of synthetic benzimidazole opioids called nitazenes. DFNZ has impaired brain penetrance, a unique spatiotemporal MOR cellular signaling profile, and diminished efficacy at the MOR–galanin 1 receptor (GAL1) heteromer. DFNZ does not induce respiratory depression, tolerance, or MOR downregulation after repeated exposure. Compared with other MOR agonists, DFNZ has limited effects on dopamine neurotransmission in the nucleus accumbens and weaker reinforcing effects in the drug self-administration procedure. These results provide novel insights about MOR and nitazene pharmacology, have important implications for pain and addiction treatment, and challenge the prevailing dogma that high-efficacy MOR agonists cannot constitute safe and effective therapeutic agents.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

49ers busca receptor en primera ronda, Eagles reestructura su juego aéreo alrededor de Devonta Smith y más NFL Draft.=============

Cannabis cessation and neurocognitive recovery: Patterns, predictors, and clinical implications—a systematic review The American Journal on Addictions  Researchers conducted a literature review of the neurocognitive effects of cannabis use and recovery from those effects. They found a range of neurocognitive effects including neuroreceptor adaptation, decrease in memory, processing speeds, and attention. Deficits increased with higher frequency and amount of use, but recovery can occur.  Receptor normalization can occur within weeks of abstinence while cognitive recovery can take months and years. Adolescent-onset users have more severe and persistent deficits, suggesting effects to neurodevelopment beyond reversible neuroadaptation. The authors suggest treatment for cannabis use disorder should focus on both the disorder and its neurocognitive effects.    Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

This podcast is a review of current literature and expert consensus regarding the periprocedural management of glucagon-like peptide (GLP) medications. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Join Digital Education Committee member and podcast host Melissa E. Middeldorp, MPH, PhD, along with this week's guest contributors,Sheldon Litwin, MD from the Medical University of South Carolina and Abhishek Deshmuckh, MBBS from the Mayo Clinic for this week's episode. This real-world retrospective cohort study evaluated whether glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy is associated with improved outcomes after atrial fibrillation (AF) ablation in obese patients using a large multicenter electronic health record database (TriNetX). After propensity matching 6,700 patients (3,350 GLP-1RA users and 3,350 non-users), GLP-1RA therapy was associated with significantly lower AF recurrence, progression to permanent AF, cardiovascular and heart failure hospitalizations, and all-cause mortality over a median ~2-year follow-up, although repeat ablation rates were unchanged. The authors propose that benefits may be mediated through weight-loss, reduction in systemic inflammation and epicardial fat, improved metabolic control, and potential direct atrial effects, but emphasize that causal inference is limited due to observational design and lack of weight-loss trajectory or adherence data. Overall, the study suggests GLP-1RAs could become an adjunct rhythm-control strategy in obese AF patients undergoing ablation, warranting prospective randomized trials.   Learning Objectives Understand the association between GLP-1 RA therapy and reduced AF recurrence and cardiovascular outcomes after catheter ablation in obese patients. Evaluate the potential mechanisms and clinical implications of GLP-1 RAs as an adjunctive metabolic therapy in rhythm control strategies for AF. Article for Discussion Article Authors Sandrine Venier, Pascal Defaye, Lisa Lochon, Rémi Benali, Arnaud Bisson, Adrien Carabelli, Youssou Diouf, Peggy Jacon, Laurent Fauchier Podcast Contributors Melissa E. Middeldorp, MPH, PhD Abhishek Deshmuckh, MBBS Sheldon Litwin, MD Host and Contributor Disclosure(s): M. Middeldorp Nothing to disclose. A. Deshmukh •Honoraria/Teaching/Speaking/Consulting: GE Healthcare   S. Litwin Honoraria/Teaching/Speaking/Consulting: Axon Therapies, Novo Nordisk, Alleviant, Corvia Medical Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study The BMJ This study investigated whether initiation of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with both reduced risks of incident alcohol, cannabis, cocaine, nicotine, opioid, and other substance use disorders (SUDs) in people with no history of SUDs (protocol 1) and with reduced risk of SUD-related adverse clinical outcomes among people with a pre-existing SUDs (protocol 2).  Researchers found that use of GLP-1 receptor agonists was consistently associated with reduced risks of developing various incident SUDs, suggesting a broad preventive effect across multiple substance types. Use was also associated with reduced risks of adverse clinical outcomes in people with pre-existing SUDs. These observational data suggest a potential role for GLP-1 receptor agonists in both the prevention and treatment of various SUDs, warranting further evaluation.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

In this 329th episode I welcome Dr. Tyler Jones, founder of the Anesthesia Thoughts Blog, to the show to discuss management of SGLT2 inhibitors and GLP1 receptor agonists. We discuss the evidence for and against holding them before surgery and what you need to know to manage patients on them.Our Sponsors:* Check out BetterHelp: https://www.betterhelp.com* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Factor: https://factormeals.com/accrac50off* Check out Quince: https://quince.com/ACCRAC* Check out Truelearn and use my code ACCRAC for a great deal: https://Truelearn.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Discutimos el trade del receptor DJ Moore a Bills además del futuro de Kenneth Walker, AJ Brown y Maxx Crosby.=============

In this episode of the Oncology Brothers podcast we navigated the rapidly evolving treatment landscape of Metastatic Hormone Receptor-Positive Breast Cancer. We were joined by Dr. Kevin Kalinsky, Director of the Breast Cancer Program at the Winship Cancer Institute, Emory University, to discuss the implications of new targeted therapies, optimal sequencing strategies, and practical toxicity management. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠  YouTube: https://www.youtube.com/@oncologybrothers •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ The discussion covered: • The critical role of NGS testing (tissue vs. liquid biopsy) in identifying PIK3CA, ESR1, AKT1 and PTEN alterations. • Frontline management of high-risk, endocrine-resistant disease with the inavolisib triplet (INAVO120) and its overall survival benefit. • Choosing between CDK4/6 inhibitors (abemaciclib vs. ribociclib) in de novo metastatic disease. • Post-CDK4/6 inhibitors on progression we covered, the use of oral SERDs (imlunestrant) and AKT inhibitors (capivasertib). • The "ADC explosion", sequencing T-DXd (DESTINY-Breast06), sacituzumab govitecan (TROPiCS-02), and datopotamab deruxtecan (TROPION-Breast01). • Clinical pearls for managing toxicities: stomatitis, hyperglycemia, rash, neutropenia, and ILD. Join us as we break down the latest data and provide actionable insights for the practicing oncologist. Don't forget to subscribe for more episodes in our breast cancer algorithm series! #MetastaticBreastCancer, #HRPositive, #ADCsequencing, #PIK3CA-AKT, #OncologyPodcast, #OncologyBrothers

In this final episode of the Progesterone Promise series, Dr. Brendan McCarthy, Chief Medical Officer of Protea Medical Center, breaks down one of the most misunderstood hormones in women's health: progesterone. Progesterone is not “good” or “bad.” It's contextual. In today's world of quick sound bites and social media medicine, hormones are often reduced to oversimplified claims like “progesterone fixes anxiety” or “progesterone causes breast cancer.” The truth? It depends on your body, your stress levels, your liver health, your inflammation, your delivery method, and whether you're using bioidentical progesterone or synthetic progestins.   Citations: 1. Oral Progesterone → First-Pass Metabolism & Allopregnanolone Claim: Oral micronized progesterone undergoes significant hepatic first-pass metabolism, increasing neuroactive metabolites (especially allopregnanolone), which positively modulate GABA-A receptors and produce sedative/anxiolytic effects. Core Evidence: Simon et al., 1993; de Lignières et al., 1995; Freeman et al., 1990 — Oral progesterone produces measurable neuroactive metabolites. Paul & Purdy, 1992; Rupprecht et al., 2001 — Allopregnanolone enhances GABA-A receptor activity. Supports: Sedation variability by route • Neurosteroid generation • GABA-A modulation 2. Sulfation vs 5α-Reduction → Opposing Neurologic Effects Claim: Progesterone metabolites can produce calming (5α-reduced) or excitatory (sulfated) neurologic effects depending on enzyme routing. Core Evidence: Majewska et al., 1990 — Pregnenolone sulfate negatively modulates GABA-A. Wu et al., 1991 — Sulfated neurosteroids enhance NMDA signaling. Schumacher et al., 2007; Reddy, 2010 — Pathway reviews of sulfation vs 5α-reduction. Supports: Reverse responding hypothesis • Divergent neurologic experiences • Enzyme-dependent effects 3. Stress & Enzyme Modulation Claim: Chronic stress alters HPA axis tone and hepatic enzyme expression, influencing steroid metabolism balance. Core Evidence: McEwen, 1998 — Allostatic load model. Charmandari et al., 2005 — Cortisol's systemic regulatory effects. Zanger & Schwab, 2013; Gibson & Skett, 2001 — Stress alters cytochrome P450 expression. Supports: Stress-biased metabolism • Context-dependent hormone response 4. Breast Tissue Signaling & Context Claim: Progesterone influences mammary differentiation and interacts with estrogen signaling in context-dependent ways. Core Evidence: Brisken & O'Malley, 2010 — Progesterone receptor biology in breast tissue. Beleut et al., 2010 — RANKL mediates progesterone-driven proliferation. Hofseth et al., 1999 — PR-ER signaling interaction. Stanczyk & Bhavnani, 2014 — Natural vs synthetic differences in breast effects. Supports: Lobuloalveolar differentiation • RANKL pathway • Context-dependent proliferation 5. Synthetic Progestins vs Bioidentical Progesterone Claim: Synthetic progestins differ structurally and bind off-target receptors, producing distinct tissue effects. Core Evidence: Stanczyk et al., 2013 — Receptor binding differences. Sitruk-Ware, 2004 — Biologic comparisons. Chlebowski et al., 2003 (WHI) — Breast cancer signal with CEE + MPA. Supports: Structural divergence • Receptor-level differences • WHI clarification 6. Route of Delivery Differences Claim: Oral, vaginal, transdermal, and sublingual progesterone produce distinct pharmacokinetic profiles and tissue targeting. Core Evidence: Simon, 1995 — Oral vs vaginal PK comparison. Cicinelli et al., 2000 — “First uterine pass effect.” Wren et al., 2003 — Route-dependent systemic levels. Supports: Uterine targeting • Neurosteroid variability • Sedation differences 7. Progesterone, PMS & Migraine Claim: Neurosteroid fluctuations influence GABAergic tone and may contribute to PMS and migraine susceptibility. Core Evidence: Backstrom et al., 2011 — Allopregnanolone fluctuations in PMS. Reddy & Rogawski, 2002 — Neurosteroids and seizure threshold. Martin & Behbehani, 2001 — Hormonal fluctuations and migraine. Supports: Luteal neurosteroid shifts • GABA instability • Migraine association   Dr. Brendan McCarthy is the founder and Chief Medical Officer of Protea Medical Center in Arizona. With over two decades of experience, he's helped thousands of patients navigate hormonal imbalances using bioidentical HRT, nutrition, and root-cause medicine. He's also taught and mentored other physicians on integrative approaches to hormone therapy, weight loss, fertility, and more. If you're ready to take your health seriously, this podcast is a great place to start.  

This week, we return to the pitch-black depths of the Scole Experiment, where a sealed room in rural Norfolk became the testing ground for an impossible claim: that voices from beyond could speak through a crude, powerless device that shouldn't have worked at all. What began as a strange experiment in energy and communication quickly drew the attention of the Society for Psychical Research — seasoned skeptics, scientists, and even magicians determined to expose any trickery. Instead, they found themselves confronting an event that challenged physics, belief, and their own assumptions. Was this the realization of a long-dreamed-of “spirit phone,” or a masterclass in deception?Visit our website for a lot more information on this episode.

In this episode of the Oncology Brothers podcast, hosts Rahul and Rohit Gosain dived deep into the evolving landscape of breast cancer treatment algorithms, focusing on early and locally advanced hormone receptor-positive breast cancer. Joined by Dr. Erica Mayer, a breast medical oncologist at the Dana-Farber Cancer Institute.  Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠  YouTube: https://www.youtube.com/@oncologybrothers/ •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ The discussion covered: • The role of chemotherapy in early-stage hormone receptor-positive breast cancer, including the use of anthracyclines versus taxane-based approaches. • Insights from the TAILORx trial and the implications of Oncotype DX scores in treatment decisions. • The ongoing OFSET trial and its potential impact on premenopausal patients with low recurrence scores. • The use of CDK4/6 inhibitors, including ribociclib and abemaciclib, in the adjuvant setting, along with their side effect profiles and dosing considerations. • The significance of the recent lidERA trial results featuring giredestrant and its implications for future treatment strategies. Join us as we explore the latest data, treatment paradigms, and the importance of patient-shared decision-making in breast cancer care. Don't forget to subscribe for more insights and staying up to date in the field of cancer.  #EarlyBreastCancer, #OncotypeDX, #CDK46inhibitors, #OralSERD, #AdjuvantTherapy, #OncologyBrothers

In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide.  This special episode is sponsored with support from Novo Nordisk. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health W. Timothy Garvey, MD.,  Butterworth Professor and University Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. Selected references: Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Knop, Filip K et al. The Lancet, Volume 402, Issue 10403, 705 – 719 Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Wharton Sean et al. N Engl J Med 2025;393:1077-1087 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff, A Michael, et al.  N Engl J Med 2023;389:2221-2232  

In this episode, we review the pharmacology, indications, adverse effects, and unique drug characteristics of 5-HT3 receptor antagonists such as ondansetron (Zofran) and palonosetron (Aloxi). Key Concepts There are four 5-HT3 (serotonin subtype 3) receptor antagonists on the market: ondansetron, granisetron, dolasetron, and palonosetron. These have primarily been studied for acute chemotherapy-induced nausea and vomiting (within 24 hours of chemotherapy administration) and for post-operative nausea and vomiting. When used for chemotherapy-induced nausea/vomiting, 5-HT3 receptor antagonists are given prior to chemotherapy (usually 30-60 minutes before) on day #1. They are not given on subsequent days because they are not as effective for delayed nausea and vomiting. Palonosetron has the longest half-life, longer binding affinity to the 5-HT3 receptor, and trends towards having the best efficacy among the 5-HT3 receptor antagonists. 5-HT3 receptor antagonists are associated with QTc prolongation and may cause headache, dizziness, constipation, or diarrhea. Their association with an increased risk of serotonin syndrome is controversial and not supported from a mechanistic perspective. References Simino GP, Marra LP, Andrade EI, et al. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2016;9(9):1183-1194. doi:10.1080/17512433.2016.1190271 Tricco AC, Soobiah C, Blondal E, et al. Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med. 2015;13:136. Published 2015 Jun 18. doi:10.1186/s12916-015-0371-y Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296 Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024;9(2):102195. doi:10.1016/j.esmoop.2023.102195 Rojas-Fernandez CH. Can 5-HT3 Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and Order. Drugs Real World Outcomes. 2014;1(1):3-5. doi:10.1007/s40801-014-0004-3 Li WS, van der Velden JM, Ganesh V, et al. Prophylaxis of radiation-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2017;6(2):104-117. doi:10.21037/apm.2016.12.01

Nicotine isn't just addictive—it might be one of the most misunderstood nootropics in modern medicine. In this masterclass, you'll learn how controlled, low-dose nicotine may enhance brain performance, boost neuroplasticity, improve mitochondrial function, and potentially extend lifespan. Host Dave Asprey breaks down the surprising science behind this controversial compound, separating fact from fear—and exposing the real risks that nobody talks about. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR You'll discover how nicotine affects neurotransmitters, why it may help with ADHD and focus, and how it compares to other cognitive enhancers like caffeine, nootropics, and even smart drugs. Dave explores how nicotine can be used to hack metabolism, enhance sleep optimization, and support fasting or ketosis protocols—if used properly. He also reveals the forms of nicotine that are safest (spoiler: it's not vapes or cigarettes), how nicotine works at the receptor level, and what the science says about long-term health effects. This episode blends functional medicine, brain optimization, and biohacking into one powerful, myth-busting breakdown. You'll Learn: • How nicotine affects mitochondria, neurotransmitters, and dopamine signaling • Why nicotine may boost neuroplasticity, memory, and attention span • How low-dose nicotine compares to caffeine, modafinil, and other nootropics • The safest delivery forms (and the ones to avoid) • Whether nicotine supports or hinders longevity and cognitive resilience • How it can be stacked with supplements, fasting, or ketosis • What functional medicine says about chronic use, addiction, and withdrawal This is essential listening for anyone serious about biohacking, human performance, and longevity, and for those who want to understand how functional biology and mitochondrial science are redefining recovery, energy, and aging. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Nicotine microdosing, Nicotinic acetylcholine receptors, Dopamine and motivation, Cognitive enhancement, Alzheimer's prevention, Neuroinflammation, Mitochondrial function, TNF-alpha reduction, Vagus nerve activation, Longevity biohacking, Nicotine vs smoking, Nootropics, Attention and vigilance, Ketosis and metabolism, Functional medicine, Nicotine patches and gum, Addiction and tolerance, Receptor desensitization, Withdrawal protocols, Deep work performance Thank you to our sponsors! -TRU KAVA | Go to https://trukava.com/ and use code DAVE10 for 10% off. -HeartMath | Go to https://www.heartmath.com/dave to save 15% off. -Leela Quantum Tech | Check out all HEAL360 products and research and get 10% off at https://leelaq.com/DAVE. -Calroy | Head to https://calroy.com/dave for an exclusive discount. Resources: • Business of Biohacking | Register to attend October 20-23 in Austin, TX https://businessofbiohacking.com/ • Danger Coffee: https://dangercoffee.com/discount/dave15 • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Introduction 1:27 — History & Background of Nicotine 4:34 — How Nicotine Works 15:12 — Benefits & Research 16:43 — Risks & Who Should Avoid It 21:39 — Delivery Methods & Dosing 26:30 — Conclusion & Next Steps See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.